Baudax Bio (BXRXQ)
OTHER OTC:BXRXQ
BXRXQ Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EST
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume10.20K
Average Volume (3M)N/A
Market Cap
$44.00
Enterprise Value$1.86M
Total Cash (Recent Filing)$363.00K
Total Debt (Recent Filing)$8.10M
Price to Earnings (P/E)―
Beta-93.23
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding43,593,082
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap42.37K
Enterprise Value/Revenue6.01
Enterprise Value/Gross Profit-0.39
Enterprise Value/Ebitda-0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BXRXQ FAQ
What was Baudax Bio’s price range in the past 12 months?
Baudax Bio lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Baudax Bio’s market cap?
Baudax Bio’s market cap is $44.00.
When is Baudax Bio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Baudax Bio’s earnings last quarter?
Currently, no data Available
Is Baudax Bio overvalued?
According to Wall Street analysts Baudax Bio’s price is currently Overvalued.
Does Baudax Bio pay dividends?
Baudax Bio does not currently pay dividends.
What is Baudax Bio’s EPS estimate?
Baudax Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Baudax Bio have?
Baudax Bio has 43,593,082 shares outstanding.
What happened to Baudax Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Baudax Bio?
Currently, no hedge funds are holding shares in BXRXQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Baudax Bio
Baudax Bio, Inc., a biopharmaceutical company established in Malvern, Pennsylvania in 2019, specializes in developing and commercializing therapeutic solutions for hospital and acute care environments. Their marketed product, ANJESO (meloxicam injection), is utilized for managing moderate to severe pain, either independently or in conjunction with other non-NSAID analgesics. The company’s pipeline includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) currently in Phase II clinical trials, and BX2000, an ultra-short-acting NMB, which is in Phase I clinical assessment. Furthermore, Baudax Bio is advancing a proprietary agent to reverse neuromuscular blockade, with BX3000, another NMB reversal agent, undergoing preclinical studies. On February 22, 2024, Baudax Bio, Inc. initiated voluntary Chapter 11 reorganization proceedings in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---